DK1471916T3 - Behandling af rheumatoid arthritis under anvendelse af imatinib - Google Patents

Behandling af rheumatoid arthritis under anvendelse af imatinib

Info

Publication number
DK1471916T3
DK1471916T3 DK03704474T DK03704474T DK1471916T3 DK 1471916 T3 DK1471916 T3 DK 1471916T3 DK 03704474 T DK03704474 T DK 03704474T DK 03704474 T DK03704474 T DK 03704474T DK 1471916 T3 DK1471916 T3 DK 1471916T3
Authority
DK
Denmark
Prior art keywords
treatment
rheumatoid arthritis
imatinib
formula
pharmaceutically acceptable
Prior art date
Application number
DK03704474T
Other languages
Danish (da)
English (en)
Inventor
Heikki Joensuu
Original Assignee
Hyks Inst Ti Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyks Inst Ti Oy filed Critical Hyks Inst Ti Oy
Application granted granted Critical
Publication of DK1471916T3 publication Critical patent/DK1471916T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Liquid Crystal Substances (AREA)
DK03704474T 2002-01-28 2003-01-27 Behandling af rheumatoid arthritis under anvendelse af imatinib DK1471916T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0201882.8A GB0201882D0 (en) 2002-01-28 2002-01-28 Organic compounds
PCT/EP2003/000802 WO2003063844A2 (fr) 2002-01-28 2003-01-27 Traitement de la polyarthrite rhumatoide

Publications (1)

Publication Number Publication Date
DK1471916T3 true DK1471916T3 (da) 2008-10-20

Family

ID=9929858

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03704474T DK1471916T3 (da) 2002-01-28 2003-01-27 Behandling af rheumatoid arthritis under anvendelse af imatinib

Country Status (23)

Country Link
US (2) US20060264443A1 (fr)
EP (1) EP1471916B1 (fr)
JP (1) JP4398731B2 (fr)
KR (1) KR101030416B1 (fr)
CN (1) CN1646130A (fr)
AT (1) ATE399555T1 (fr)
BR (1) BR0307286A (fr)
CA (1) CA2473158C (fr)
DE (1) DE60321888D1 (fr)
DK (1) DK1471916T3 (fr)
ES (1) ES2309299T3 (fr)
GB (1) GB0201882D0 (fr)
HK (1) HK1072192A1 (fr)
IL (1) IL162983A (fr)
MX (1) MXPA04007309A (fr)
NO (1) NO328255B1 (fr)
NZ (1) NZ534137A (fr)
PL (1) PL212137B1 (fr)
PT (1) PT1471916E (fr)
RU (1) RU2322238C2 (fr)
SI (1) SI1471916T1 (fr)
WO (1) WO2003063844A2 (fr)
ZA (1) ZA200405323B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080061A1 (fr) * 2002-03-21 2003-10-02 Dana-Farber Cancer Institute, Inc. Inhibition de reponses de mort cellulaire induite par stress oxydatif
US20050130986A1 (en) * 2003-11-21 2005-06-16 Eklund Kari K. Treatment of spondylarthropathies
US20080248022A1 (en) * 2004-09-08 2008-10-09 Immunaid Pty Ltd Therapeutic Strategy for Treating Autoimmune and Degenerative Diseases
EP2076266A2 (fr) * 2006-05-31 2009-07-08 The Board of Trustees of the Leland Stanford Junior University Procédé de traitement de maladies inflammatoires utilisant des inhibiteurs de tyrosine kinase
CN102512421B (zh) * 2011-10-28 2013-11-06 中国科学院广州生物医药与健康研究院 哌嗪酰胺类化合物在制药中的应用
KR101386697B1 (ko) 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
RU2580656C1 (ru) * 2014-11-20 2016-04-10 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма гидроксихлорохина немедленного высвобождения и способ ее получения
WO2020078454A1 (fr) * 2018-10-18 2020-04-23 Sinomab Bioscience Limited Procédé de modulation de l'auto-immunité par rupture de la liaison cis-ligand d'antigènes de type siglec
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316884A (en) * 1979-01-25 1982-02-23 Adria Laboratories, Inc. Sustained release pharmaceutical formulation
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
CO5200760A1 (es) * 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds
WO2002083075A2 (fr) * 2001-04-16 2002-10-24 Uab Research Foundation Akt et regulation de l'apoptose des fibroblastes synoviaux de polyarthrite rhumatoide (ra)
PL392652A1 (pl) * 2001-05-16 2010-12-06 Novartis Ag Kombinacja zawierająca N-{5-[4-(4-metylo-piperazyno-metylo)-benzoiloamido]-2-metylofenylo}-4-(3-pirydylo)-2-pirymidyno-aminę oraz środek chemoterapeutyczny, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca oraz zestaw zawierający taką kombinację
ATE330608T1 (de) * 2001-06-29 2006-07-15 Ab Science Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen

Also Published As

Publication number Publication date
CA2473158A1 (fr) 2003-08-07
EP1471916B1 (fr) 2008-07-02
HK1072192A1 (en) 2005-08-19
EP1471916A2 (fr) 2004-11-03
RU2322238C2 (ru) 2008-04-20
JP2005526022A (ja) 2005-09-02
NO20043585L (no) 2004-10-21
RU2004126447A (ru) 2005-07-10
US20060264443A1 (en) 2006-11-23
ZA200405323B (en) 2005-08-31
SI1471916T1 (sl) 2008-12-31
PL370264A1 (en) 2005-05-16
NZ534137A (en) 2007-03-30
ATE399555T1 (de) 2008-07-15
BR0307286A (pt) 2004-12-28
PT1471916E (pt) 2008-10-03
KR101030416B1 (ko) 2011-04-20
CA2473158C (fr) 2013-06-11
PL212137B1 (pl) 2012-08-31
GB0201882D0 (en) 2002-03-13
WO2003063844A2 (fr) 2003-08-07
DE60321888D1 (fr) 2008-08-14
US20090131382A1 (en) 2009-05-21
WO2003063844A3 (fr) 2004-04-01
CN1646130A (zh) 2005-07-27
NO328255B1 (no) 2010-01-18
KR20040086301A (ko) 2004-10-08
ES2309299T3 (es) 2008-12-16
MXPA04007309A (es) 2005-09-12
IL162983A (en) 2010-06-16
JP4398731B2 (ja) 2010-01-13

Similar Documents

Publication Publication Date Title
DK1332137T3 (da) Behandling af gastrointestinale stromale tumorer
HK1072192A1 (en) Treatment of rheumatoid arthritis using imatinib
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
ATE468855T1 (de) Kombination von stickstoff-senf analogen und imatinib für die behandlung von chronischer lymphatischer leukämie
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
AU2003216621A8 (en) Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
ATE326970T1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen
WO2004103374A3 (fr) Traitement des cancers de la tete ou du cou